The Potential of Carnosine in Brain-Related Disorders: A Comprehensive Review of Current Evidence
Year: 2019
Type: review
Abstract: Neurological, neurodegenerative, and psychiatric disorders represent a serious burden because of their increasing prevalence, risk of disability, and the lack of effective causal/disease-modifying treatments. There is a growing body of evidence indicating potentially favourable effects of carnosine, which is an over-the-counter food supplement, in peripheral tissues. Although most studies to date have focused on the role of carnosine in metabolic and cardiovascular disorders, the physiological presence of this di-peptide and its analogues in the brain together with their ability to cross the blood-brain barrier as well as evidence from in vitro, animal, and human studies suggest carnosine as a promising therapeutic target in brain disorders. In this review, we aim to provide a comprehensive overview of the role of carnosine in neurological, neurodevelopmental, neurodegenerative, and psychiatric disorders, summarizing current evidence from cell, animal, and human cross-sectional, longitudinal studies, and randomized controlled trials.
Source: Nutrients
DOI: 10.3390/nu11061196
Authors: Martin Schön, Aya Mousa, Michael Berk, Wern L. Chia, Jozef Ukropec, Arshad Majid, Barbara Ukropcová, Barbora de Courten
Institutions: Slovak Academy of Sciences, Biomedical Research Center of the Slovak Academy of Sciences, Comenius University Bratislava, Monash University, Barwon Health, Deakin University, The University of Melbourne, Florey Institute of Neuroscience and Mental Health, Orygen, University of Sheffield
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,026
Funders: Slovak Academic Information Agency, National Institute for Health and Care Research, National Heart Foundation of Australia, Monash University, Agentúra na Podporu Výskumu a Vývoja, Vedecká Grantová Agentúra MŠVVaŠ SR a SAV, Medical Research Council, National Health and Medical Research Council, NIHR Sheffield Clinical Research Facility, NIHR Sheffield Biomedical Research Centre
Awards: G2237749857, G2594711249, G3663434371, Novel therapies for psychiatric disorders, Molekulárne mediátory účinkov fyzickej aktivity a karnozínu u pacientov s preklinickými a včasnými štádiami neurodegeneratívnych ochorení., G7284716197, Synergické účinky cvičenia a suplementácie karnozínom na motoriku, metabolizmus a charakteristiky kostrového svalu u pacientov vo včasných štádiách Parkinsonovej choroby., Novel therapies, risk pathways and prevention of mood disorders
OpenAlex ID: W2947338824